CRBN Protein Induces Neural Stem Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research lacks a factor that effectively induces differentiation of neural stem cells or neural progenitor cells into nerve cells, hindering brain regeneration in diseases such as Alzheimer's.
Innovation Solution
The protein CRBN is identified to induce proliferation and differentiation of central nervous stem cells or neural progenitor cells into nerve cells, functioning downstream of Lhx2 and forming a ubiquitin ligase complex with proteins like DDB1, Cul4A, and Roc1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current research methods are used to study neural stem cell differentiation, then existing knowledge about Lhx2 and other factors is maintained, but the ability to discover new differentiation-inducing factors is limited
Solution Approach 1:
The patent uses CRBN as an intermediary factor that mediates the differentiation process between Lhx2 and neural stem cells. By identifying CRBN as a downstream target of Lhx2, the research establishes a new intermediary in the differentiation pathway, enabling discovery of previously unknown mechanisms while maintaining the reliability of existing Lhx2 knowledge.
Solution Approach 2:
The patent performs preliminary identification and characterization of CRBN's role in neural stem cell differentiation before fully understanding its mechanisms. By preliminarily establishing CRBN as a differentiation-inducing factor and its relationship with Lhx2, the research creates a foundation for further systematic study of the differentiation pathway.
2Productivity
If CRBN is identified as a new differentiation factor, then brain regeneration capability is improved, but the complexity of the differentiation pathway increases
Solution Approach 1:
The patent segments the neural stem cell differentiation pathway into distinct functional components: Lhx2 as an upstream regulator, CRBN as a downstream effector, and the ubiquitin ligase complex as the molecular machinery. This segmentation allows each component to be studied and manipulated independently, managing complexity while enabling targeted intervention to enhance brain regeneration.
Solution Approach 2:
CRBN serves as a critical intermediary that translates Lhx2 signaling into differentiation outcomes through its role in the ubiquitin ligase complex. By introducing this intermediary layer, the system gains regulatory control points that can be targeted therapeutically, improving regeneration capability without overwhelming complexity.
3Reliability
If CRBN and its ubiquitin ligase complex components are used as therapeutic targets, then treatment efficacy for cerebral cortex diseases is improved, but the number of required components increases
Solution Approach 1:
The patent identifies that CRBN, as part of the DDB1-CUL4A ubiquitin ligase complex, performs multiple functions: it regulates neural stem cell differentiation, responds to Lhx2 signaling, and maintains protein homeostasis through ubiquitination. By targeting CRBN, a single component can influence multiple aspects of the differentiation process and disease pathology, improving treatment efficacy without requiring simultaneous administration of multiple separate components.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided.